Escient Pharmaceuticals
Targeted therapeutics for neurosensory-inflammatory disorders
San Diego, United States
39 employees
Series C
Total: $237.50M
Biotechnology, Health and Wellness +1
General Information
San Diego, United States
BounceWatch is an independent company data service, not affiliated with Escient Pharmaceuticals. To contact Escient Pharmaceuticals, visit escientpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biotechnology
About Escient Pharmaceuticals
Taxonomy: clinical-stage pharmaceutical company, targeted therapeutics, neurosensory-inflammatory disorders, MRGPRX2 antagonist, MRGPRX4 antagonist, mast cell-mediated disorders, cholestatic pruritus, San Diego, GPCR drug discovery, life science investors
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | $120.00M | 10 |
|
28 Nov 2022 |
| Series B | $77.50M | - |
|
14 Sep 2020 |
| Series A | $40.00M | - |
|
09 May 2018 |
Escient Pharmaceuticals Alternatives & Competitors
View All Alternatives
Pioneering science for patient choice
Pioneering Therapeutics to Combat Inflammatory Diseases, Pioneering Better Health
Pioneering RNA-targeted therapies with rapid LNA-based drug development for diverse disease states.
FAQ About Escient Pharmaceuticals
Source: BounceWatch company record for Escient Pharmaceuticals, https://bouncewatch.com/company/escient-pharmaceuticals, updated 30 December 2024. When citing, please name BounceWatch and link this page.
